

ASX Release

Investor presentation and strategy update

BRISBANE, 18th July 2018: Anataro Lifesciences (ASX:ANR) is pleased to release its latest presentation and strategy update that will be delivered to institutional investors this week.

In outlining its future strategy, Anataro has provided an update on its efforts to develop its product pipeline, extending from its core application to control diarrhoea in pigs, to the management of human gastrointestinal disorders such as Irritable Bowel Syndrome and Inflammatory Bowel Disease.

The presentation also summarises:

- The exclusive global agreement with Zoetis for the worldwide development, manufacturing, distribution and marketing of Detach in livestock and horses
- Anataro's human gastrointestinal program which has been reviewed and refined, resulting in a strong lead product for restoring and maintaining gut health
- Enhancement of Anataro's Intellectual Property position
- Confirmation that the Company has funding in place to progress the first human product through to anticipated partnering

A copy of the investor presentation follows. A letter to shareholders has also been lodged today which provides further context to Anataro's strategy moving forward.

For more information please contact:

Investor inquiries	Media inquiries
Dr Jay Hetzel, Chairman Anataro Lifesciences +61 (0) 7 3394 8202 jhetzel@anataro.com	Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anataro Lifesciences

Anataro Lifesciences (ASX: ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anataro granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anataro is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anatarolifesciences.com.

For personal use only



From animals to humans

July 2018

Dr Jay Hetzel, Chairman
Dr Tracie Ramsdale, CEO
Dr Tracey Brown, CDO
Anatara Lifesciences (ASX:ANR)



ANATARA
LIFESCIENCES

For personal use only

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Anatara Corporate History

For personal use only



Presentation Highlights

- Signed exclusive global agreement with Zoetis for the worldwide development, manufacturing, distribution and marketing of Detach in livestock and horses
- Human gastrointestinal program reviewed and refined, resulting in strong initial candidate for restoring and maintaining gut health
- Enhanced IP position
- Funding in place to progress the first human product through to anticipated partnering in 2020
- Current cash \$8.8 million.*

Anatara develops and aims to partner non-antibiotic, oral products for gastrointestinal disease in humans where there is significant unmet need and large market opportunity

* Appendix 4C - 31 March 2018



Animal Health

- A natural, safe, non-antibiotic product that aids in the control of diarrhea (known as scour) in livestock
- Anantara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacturing, distribution, and marketing of Detach for livestock animals and horses
- Upfront payment of US\$2.5m, aggregate milestone payments of up to US\$6.3m and royalty of 3-4%



For personal use only



From animals to humans

Anatara's Technology

- **Bromelain** is a natural product extracted from pineapple stems.
- Based on decades of research by world-class academic and commercial partners which found that bromelain contains a number of proteases with distinct biological activities, including
 - Anti-attachment
 - Anti-secretory
 - Anti-inflammatory

Potential applications in humans include gastrointestinal (GI) diseases that involve inflammation and/or diarrhea



Anatara molecules are extracted from "stems" of the pineapple plant

Human strategy – strategic review

- Potential applications for Anantara's technology exist in
 - childhood diarrhea
 - traveller's diarrhea
 - diarrhea associated with gastrointestinal disorders such as IBD and IBS
- Following a thorough review of each of these opportunities, the IBD/IBS indication was selected on the basis of:
 - Market potential
 - Competitive advantage
 - Quality of supporting data
 - Strength of intellectual property protection
 - Speed to market
- Anantara has elected to develop a novel product aimed at promoting gut health and managing the symptoms associated with gastrointestinal disorders such as IBD and IBS
- Leveraging off large amount of data previously generated

For personal use only



About Inflammatory Bowel Disease (IBD)

For personal use only

- Two forms: Ulcerative Colitis and Crohn's Disease
- Patients experience abdominal pain and cramping, bloating, blood and mucus in the stool, loss of appetite and persistent diarrhea
- Treatment involves suppressing inflammation with the goal of inducing and maintaining remission
- 30-50% of IBD patients² turn to complementary and alternative medicines



>5m
IBD sufferers
worldwide¹

IBD is a global disease with accelerating incidence in newly industrialised countries




¹Crohn's and Colitis Australia

²Gastroenterology 2017; 152:415-429

About Irritable Bowel Syndrome (IBS)

For personal use only

- IBS is a functional disorder. Incomplete knowledge of pathology, therefore the approach is symptom management
- Symptoms include abdominal pain, bloating and alternating constipation and diarrhea
- Patients have a poor quality of life and utilise the healthcare system more than other patients
- ~50% of patients⁴ turn to dietary supplements and complementary medicines



25B USD
GI and Digestive
Health
Nutraceuticals
Market*

36B USD
by 2021
CAGR 8%*

Affects
around 11%
of the global
population³

The most commonly diagnosed gastrointestinal condition and a significant health care burden

³Clinical Gastroenterology and Hepatology 2012; 10, 712-721

⁴World J. Gastroenterol 2014; 346-362

Anatara has designed a novel product aimed at restoring and maintaining gut health:

**Gastrointestinal
Reprogramming
Product (GaRP)**

For the Management
of Gastrointestinal
Disorders



Target Gastrointestinal Disorders

Irritable Bowel Syndrome (IBS)

Low grade **inflammation**

Inflammatory Bowel Disease (IBD)

Chronic **inflammation**

Shared disease characteristics:

Altered microbiome
Impaired intestinal barrier function
Mucosal damage

IBS and IBD are areas of significantly unmet clinical need

Anatara's GaRP aims to:

- Re-establish the homeostasis of the gut microbiome
- Treat the inflammation
- Repair the mucosal damage

THEREBY reduce the associated diarrhea.



The Microbiome and IBD/IBS

For personal use only

Healthy gut microbiome

- Supplies energy and nutrients
- Immune system development
- Defence against pathogens



Healthy gut – increased diversity

IBD/IBS gut microbiome


- Less bacteria with anti-inflammatory properties
- More bacteria with pro-inflammatory properties
- Reduction of diversity
- Change in overall bacteria numbers



Unhealthy gut – lack of diversity

How GaRP works?

GaRP is a microbiome-targeted dietary supplement aimed at:




GaRP will be used as an **adjunct** to existing treatments.



Dietary Supplements as an adjunct to prescription drugs for the treatment of GI disorders

- GI disorders affect a significant proportion of the population.
- ~50% of patients seek additional relief of their symptoms through adjunct therapies
- Increased education and more detailed evaluation of dietary supplements has led to healthcare providers working with patients to develop individualised programs which include dietary supplements in the symptom management for GI disorders.





GaRP – built on strong scientific foundations



About bromelain

For personal use only



Generally Recognised as Safe (GRAS)

Bromelain is allowed in food as a food additive and it has been affirmed as Generally Recognised as safe (GRAS) allowing it to be **considered as a food**.



Unlimited Acceptable Daily Intake (ADI)

Bromelain has been used for decades in as an anti-inflammatory and anti-cancer complementary medicine in the USA and Europe. This has established it to be safe with an **unlimited Acceptable Daily Intake**



But formal clinical data has been lacking

A lot of anecdotal evidence regarding its clinical efficacy but the bromelain is poorly characterised and therefore has variable activity resulting in **no definitive clinical data**




Until now...

Anatara has developed a **bromelain fingerprint** where different biological activities are associated with specific parts of the bromelain fingerprint

This will be utilised in our human therapeutic programs





Dual targeted product combining bromelain and other GRAS components*

Ileum targeted components

- prevent attachment of pro-inflammatory bacteria
- restore gut microbiota
- reduce inflammation

Colon targeted components

- restore gut microbiota
- reduce inflammation
- mucosa regeneration
- restore gut integrity
- reduce diarrhea

* Provisional patent application filed August 2017

GaRP Development Plan– next steps

- **Proof of concept studies** are well advanced to demonstrate that GaRP can:
 - Remove bacteria with pro-inflammatory properties
 - Reduce inflammation by reducing the release of proinflammatory cytokines
 - Reduce serotonin-induced diarrhea (important for IBS)
 - Regenerate the integrity of the gastrointestinal tract
 - Stimulate mucosal healing
- **Formulation Development** – coated, dual-release preparation
- **Dose Optimisation & Efficacy Testing** – in pigs (preclinical development in an adult pig model reduces the risk of formulation failure in a human)



Regulatory advantages of dietary supplements*

The advantages of a dietary supplement regulatory strategy are:

1. Less expensive and less risky pathway to market
2. Rapid market entry
3. Public and healthcare professionals understand the term 'dietary supplement'
4. Marketing can be aimed at both the public and the professional.

* Dietary Supplements are foods intended to supplement the normal diet which are concentrated sources of one or more nutrients, like vitamins, proteins, mineral complexes, herb or other botanical, amino acid or enzymes.



A clear path to commercialisation

For personal use only

	2017 H1	2017 H2	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2
Confirmed GRAS status for components with FDA	✓							
Established collaboration with University of Liverpool (UK)		✓						
Completed product development plan		✓						
Patent Application filed		✓		✓				
Commercial feasibility			✓					
Manufacturing – sourced suppliers		✓						
Proof of concept			→					
Efficacy studies					→			
Partnering discussions			→				→ *	



Investment Summary

- **GaRP** a large addressable and growing market and rapid development path
- **Anatara** has the funds necessary to progress GaRP through to a partnering deal in 2020
- **Anatara** has initiated discussions with sector specialists to maximise the commercial potential of a GaRP partnering deal
- **Anatara** will further strengthen the Board & Management
- **Anatara** aims to broaden its GI pipeline through collaborations and possible in-licensing opportunities



Thank you

Dr Jay Hetzel, Chairman
jhetzel@anataralifesciences.com

Dr Tracie Ramsdale, CEO & Director
tramsdale@anataralifesciences.com

Dr Tracey Brown, Chief Development Officer
tbrown@anataralifesciences.com

www.anataralifesciences.com

 @AnataraANR

